3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Stomach Neoplasms
3
Pancreatic Neoplasms
3
Lung Neoplasms
2
Carcinoma, Renal Cell
2
Adenocarcinoma Of Esophagus
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Lung Diseases
1
Kidney Neoplasms
1
Esophageal Neoplasms
1
Erythrocytosis, Familial, 4
1
Cholangiocarcinoma
1
Advanced Non-Small Cell Lung Cancer
1
Interventions
Oxaliplatin
7
Fluorouracil
7
Paclitaxel
5
Leucovorin
5
pembrolizumab
4
Trastuzumab
4
Radiation
4
Capecitabine
4
tislelizumab
3
Taxes
3
Specimen Handling
3
Nivolumab
3
Carboplatin
3
ulixertinib
2
trastuzumab biosimilar HLX02
2
patritumab deruxtecan
2
Surgical Procedures, Operative
2
Radiotherapy
2
Pemetrexed
2
PF-05280014
2
Ontruzant
2
Ogivri
2
Irinotecan
2
Exercise
2
Docetaxel
2
Cisplatin
2
CT-P6
2
zolbetuximab
1
zimberelimab
1
zanidatamab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
zimberelimab
×
30 days
×
Clear all
NCT05891171
2026-06-05
ARC-25
Arcus Biosciences, Inc.
Phase 1
Active not recruiting
40 enrolled